Shares in Novocure (NSDQ:NVCR) fell today after the oncology company missed expectations on Wall Street with its second quarter results.
The St. Helier, N.J.-based company reeled in its losses to -$21.2 million on sales of $38.4 million for the 3 months ended June 30, for bottom-line growth of 48% on sales growth of 114% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure misses sales, earnings estimates in Q2 appeared first on MassDevice.
from MassDevice http://ift.tt/2tMRPyQ
Cap comentari:
Publica un comentari a l'entrada